Mitomycin-C Kyowa 40 mg - Important Safety Information from Kyowa Kirin Holdings B.V. as approved by the HPRA

Notice type: 3rd Party Publications

Date: 15/10/2019

 

Problem Or Issue:
Important Safety Information from Kyowa Kirin Holdings B.V. - Mitomycin-C Kyowa 40 mg restricted to intravesical administration only for treatment of superficial bladder cancer

Important Safety Information - Mitomycin-C Kyowa 40 mg



« Back